GlassScriptPhysician profile
Eduardo Viera
NPI 1144273426
$3,390.81
in general payments reported to CMS, 2019-2025
27 companies · $44.56 in 2025
The $44.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $633 · 2021: $260 · 2022: $103 · 2023: $80.21 · 2024: $1,594 · 2025: $44.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,378 · Food and Beverage: $290 · Travel and Lodging: $51.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,377.50 |
| Food and Beverage | $290.30 |
| Travel and Lodging | $51.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,954.04 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $707.91 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $107.26 | 2019-2022 | |
| Astellas Pharma US INC | $97.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $75.30 | 2020 | |
| Lilly USA, LLC | $65.06 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $59.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.55 | 2019-2023 | |
| Amgen INC. | $55.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.97 | 2019 | |
| Alkermes, INC. | $22.73 | 2025 | Aristada, Lybalvi |
| Tris Pharma INC | $21.83 | 2025 | Dyanavel Xr |
| Allergan, INC. | $18.83 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $17.42 | 2021 | |
| Abbvie INC. | $15.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.45 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Viera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.